Chengdu Technology Innovation Investment Group
成都科创投
elsewhere's corpus doesn't contain a direct profile of Chengdu Technology Innovation Investment Group (成都科创投) — it appears only as an investor in deal announcements, so details like its founding, AUM or ownership aren't covered. What those announcements do show is an active Chengdu-based investor leaning into frontier tech: it co-led the Pre-A round of biotech startup 演生潮 alongside Qiming Venture Partners and others (per Qiming, August 2025) , joined the C1 round of smart-glasses maker INMO at a RMB 2 billion valuation (per Unity Ventures, January 2026) , took part in Galaxy Universal's RMB 2.5 billion round alongside the National AI Industry Investment Fund and other state-backed investors (per Source Code Capital, March 2026) , and backed Zhitai Bio's nearly RMB 200 million Series B+ in 2023 (per BlueRun Ventures) . Read together, the pattern is a state-affiliated Chengdu fund writing checks across robotics, biotech and AI hardware — but that characterization is inference from its deal list, not a sourced description of the group itself.
AI-generated — may contain errors, please verify.
Coverage
MaKe | MaHui Member "Galaxy Universal" Announces 2.5 Billion Yuan Funding Round, Source Code Capital Participates in Angel Round and Two Subsequent Rounds
The Year's Largest Embodied Artificial Intelligence Funding Round
StarSilk Completes Multiple Strategic Funding Rounds, Deepening Focus on Commercial Aerospace and 5G/6G Satellite Internet
Solidifying leadership in 5G NTN direct-to-cell satellite baseband SoC chips.
Smart glasses maker INMO closes C1 round, its third in a year | Unity Ventures portfolio news
Total funding raised: nearly 500 million yuan
Evolutionary Tide Raises Hundreds of Millions of Yuan in Pre-A Round, Qiming Venture Partners Co-Leads
Emergent Tide is built on original research from the Tsinghua University School of Medicine team in the field of humoral immunity, developing novel therapeutics for inflammatory and autoimmune diseases against a first-in-class global target, addressing core challenges in the field and significant unmet clinical needs.
BlueRun Ventures | BlueRun Ventures Continues to Double Down, Zhitai Bio Closes Nearly RMB 200 Million Series B+ Round
Focused on developing recombinant protein therapeutics using an *E. coli*-based technology platform.
